Pieris Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Revenue (Tables)

Revenue (Tables)

3 Months Ended

Mar. 31, 2019

Revenue from Contract with Customer [Abstract]

During the three months ended March 31, 2019 and 2018, respectively, the Company recognized revenues as follows (in thousands):



	Three Months Ended March 31
	2019		2018
Revenue from contracts with customers	$	7,534	$	3,444
Collaboration revenue (ASC 808)	1,011		617
Other revenues	—		91
Total Revenue	$	8,545	$	4,152

Included in the revenue from contracts with customers for the three months ended March 31, 2019 was $4.3 million that was included in the aggregated deferred liability balances at December 31, 2018.

During the three months ended March 31, 2019 and 2018, respectively, the Company recognized revenue from the following strategic partnerships and other license agreements (in thousands):



	Three Months Ended March 31
	2019		2018
Seattle Genetics	$	925	$	308
AstraZeneca	6,020		2,545
Servier	1,600		1,208
Other	—		91
Total Revenue	$	8,545	$	4,152

Schedule of Potential Milestone Payments

Under the Company´s existing strategic partnerships, the Company could receive the following potential milestone payments (in millions):



	Research, Development & Commercial Milestones		Sales Milestones
Seattle Genetics	$	769	$	450
AstraZeneca	1,111		960
Servier	971		881
Total potential milestone payments	$	2,851	$	2,291